title: 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma.
abstract: BACKGROUND
  Although intra-arterial radiation therapy with 131I-lipiodol is a useful therapeutic approach to the treatment of hepatocellular carcinoma, various disadvantages limit its use.
  
  
  OBJECTIVE
  To describe the development of a method for the labelling of lipiodol with 188Re-SSS (188Re (S2CPh)(S3CPh)2 complex) and to investigate its biodistribution after injection into the hepatic artery of rats with hepatoma.
  
  
  METHODS
  188Re-SSS lipiodol was obtained after dissolving a chelating agent, previously labelled with 188Re, in cold lipiodol. The radiochemical purity (RCP) of labelling was checked immediately. The 188Re-SSS lipiodol was injected into the hepatic artery of nine rats with a Novikoff hepatoma. They were sacrificed 1, 24 and 48 h after injection, and used for ex vivo counting.
  
  
  RESULTS
  Labelling of 188Re-SSS lipiodol was achieved with a yield of 97.3+/-2.1%. The immediate RCP was 94.1+/-1.7%. Ex vivo counting confirmed a predominantly hepatic uptake, with a good tumoral retention of 188Re-SSS lipiodol, a weak pulmonary uptake and a very faint digestive uptake. The 'tumour/non-tumoral liver' ratio was high at 1, 24 and 48 h after injection (2.9+/-1.5, 4.1+/-/4.1 and 4.1+/-0.7, respectively).
  
  
  CONCLUSIONS
  Using the method described here, 188Re-SSS lipiodol can be obtained with a very high yield and a satisfactory RCP. The biodistribution in rats with hepatoma indicates a good tumoral retention of 188Re-SSS lipiodol associated with a predominant hepatic uptake, a weak pulmonary uptake and a very faint digestive uptake. This product should be considered for intra-arterial radiation therapy in human hepatoma.
authors.affiliation: UPRES EA 1794/Service de Médecine Nucléaire Centre Eugène Marquis, Rennes, France. etienne.garin@univ-rennes1.fr
authors.forename: Etienne
authors.initials: E
authors.lastname: Garin
authors.forename: Benoit
authors.initials: B
authors.lastname: Denizot
authors.forename: Nicolas
authors.initials: N
authors.lastname: Noiret
authors.forename: Nicolas
authors.initials: N
authors.lastname: Lepareur
authors.forename: Jerome
authors.initials: J
authors.lastname: Roux
authors.forename: Myriam
authors.initials: M
authors.lastname: Moreau
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Herry
authors.forename: Patrick
authors.initials: P
authors.lastname: Bourguet
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Benoit
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Lejeune
mesh_terms: D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D005260:Female; D007269:Injections, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D007553:Isotope Labeling / Q000379:methods*; D008113:Liver Neoplasms / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D009928:Organ Specificity; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution; D014915:Whole-Body Counting
chemical_list: D004338:Drug Combinations; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C494618:rhenium-SSS-lipiodol; D007459:Iodized Oil